AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
201.47
+2.83 (1.42%)
At close: Aug 13, 2025, 4:00 PM
201.50
+0.03 (0.01%)
After-hours: Aug 13, 2025, 7:52 PM EDT
AbbVie Revenue
AbbVie had revenue of $15.42B in the quarter ending June 30, 2025, with 6.65% growth. This brings the company's revenue in the last twelve months to $58.33B, up 6.05% year-over-year. In the year 2024, AbbVie had annual revenue of $56.33B with 3.71% growth.
Revenue (ttm)
$58.33B
Revenue Growth
+6.05%
P/S Ratio
6.11
Revenue / Employee
$1,060,509
Employees
55,000
Market Cap
355.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 56.33B | 2.02B | 3.71% |
| Dec 31, 2023 | 54.32B | -3.74B | -6.44% |
| Dec 31, 2022 | 58.05B | 1.86B | 3.30% |
| Dec 31, 2021 | 56.20B | 10.39B | 22.69% |
| Dec 31, 2020 | 45.80B | 12.54B | 37.69% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
| Thermo Fisher Scientific | 43.21B |
ABBV News
- 13 hours ago - My Dividend Stock Portfolio: New July Dividend Record - 100 Holdings With 12 Buys - Seeking Alpha
- 1 day ago - AbbVie: H1 2025 Earnings Strengthen Case For Targeting Gilgamesh Acquisition - Seeking Alpha
- 1 day ago - AbbVie Announces $195 Million Investment to Expand Active Pharmaceutical Ingredient Manufacturing in the U.S. - PRNewsWire
- 5 days ago - Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79% - Benzinga
- 7 days ago - Get Ready, JUVÉDERM® Day is Calling! - PRNewsWire
- 8 days ago - Allergan Aesthetics Unveils the New Faces of Natrelle® and Real Stories of Empowerment and Transparency - PRNewsWire
- 12 days ago - AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion - Benzinga
- 12 days ago - 5 Dividend Stocks With Solid Returns And More Growth Ahead - Benzinga